SCHEMBL6440924

SCHEMBL6440924

O=C(O)c1cccc(Cn2nnc(-c3ccc(F)c4c(C(=O)C(=O)N5CCN(C(=O)c6ccccc6)CC5)c[nH]c34)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
CYP2C9 P11712 2/20 0.43
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2B6 P20813 1/20 0.40
CYP2C19 P33261 1/20 0.40
KCNH2 Q12809 1/20 0.40
HDAC6 Q9UBN7 1/20 0.38
TSHR P16473 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
FAAH O00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443804 0.95 CYP2C9 (0.42) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6442058 0.94 CYP2C9 (0.46) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6440957 0.92 CYP2C9 (0.44) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6443626 0.92 CYP2C9 (0.45) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6441372 0.89 CYP2C9 (0.44) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6444031 0.89 CYP2C9 (0.44) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4
SCHEMBL6442503 0.87 CYP2C9 (0.46) RAB9ANPC1CYP2C9CYP3A4CYP1A2
SCHEMBL6445359 0.86 CYP2C9 (0.47) RAB9ANPC1CYP2C9CYP3A4CYP1A2
SCHEMBL6442558 0.86 CYP2C9 (0.49) RAB9ANPC1CYP2C9CYP3A4CYP1A2
SCHEMBL6442773 0.86 CYP2C9 (0.46) SMN1; SMN2RAB9ANPC1CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA SMN1; SMN2 4831/4885RAB9A 4168/4885NPC1 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.